Veracyte (VCYT) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $115.9 million, up 29% year-over-year, driven by 34% testing revenue growth and higher volumes for Decipher and Afirma; total test volume ranged from 36,792 to 39,032.

• Net income for Q3 2024 was $15.2 million, a significant improvement from a net loss in Q3 2023, with adjusted EBITDA of $27.3 million (24% of revenue).

• Cash and cash equivalents ended Q3 at $274.1 million, with strong cash generation from operations.

• The C2i Genomics acquisition in February 2024 expanded MRD detection capabilities and added $56.0 million in goodwill.

• Strategic focus includes expanding Decipher and Afirma, launching IVD and MRD products, advancing international growth, and strengthening leadership.

Financial highlights

• Total Q3 revenue: $115.9 million, up 29% year-over-year; testing revenue: $109.5 million, up 34%; product revenue: $3.2 million, down 21%; biopharma/other revenue: $3.1 million, down 23%.

• Non-GAAP gross margin: 71% (up from 70% YoY); GAAP gross margin: 68%.

• Adjusted EBITDA: $27.3 million (24% of revenue); non-GAAP net income: $25.99 million; diluted EPS: $0.19; non-GAAP diluted EPS: $0.33.

• Cash from operations for Q3: $30.0 million; nine-month cash from operations: $50.6 million.

• Operating expenses: $67.0 million; non-GAAP operating expenses: $57.6 million, up 11% year-over-year.

Outlook and guidance

• 2024 revenue guidance raised to $442–$445 million (22–23% YoY growth), with testing revenue growth expected at ~28%.

• Full-year 2024 adjusted EBITDA margin expected to exceed 20%.

• Year-end 2024 cash expected between $280–$285 million, including $10–$15 million in milestone payments and capex.

• High single-digit growth projected for Afirma in 2025; continued investment in MRD and IVD test development and international expansion.

• Macroeconomic and geopolitical risks, including inflation and conflicts, are being closely monitored.